The pharmacokinetics of octreotide in cirrhosis and in healthy man

Journal of Hepatology

Volumn 26, Issue 5, 1997, Pages 1018-1025

  Ottesen, Lone Harild ^a   Flyvbjerg, Allan ^a   Jakobsen, Preben ^a   Bendtsen, Flemming ^a  

^a NONE

Author keywords

Area under curve; Cirrhosis; Clearance; Half life; Octreotide; Pharmacokinetics; Volume of distribution

Indexed keywords

OCTREOTIDE;

ADULT; ARTICLE; BOLUS INJECTION; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE LIVER FUNCTION RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER CIRRHOSIS; LIVER CLEARANCE; MALE; PRIORITY JOURNAL;

EID: 0030917283     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(97)80110-9     Document Type: Article

References (41)

1. Sung JJY, Chung SCS, Lai C-W, Chan FKL, Leung JWC, Yung M-Y, Kassianides C, Li AKC. Octreotide infusion or emergency sclerotherapy for variceal hemorrhage. Lancet. 342:1993;637-641.
2. Silvain C, Carpentier S, Sauterau D, Czernichow B, Métreau J-M, Fort E, Ingrand P, Boyer J, Pillegand B, Doffél M, Dhumeaux D, Beauchant M. Terlipressin plus transdermal nitroglycerin vs. octreotide in the control of acute bleeding from esophagal varices: a multicenter randomized trial. Hepatology. 18:1993;61-65.
3. Besson I, Ingrand P, Person B, Boutroux D, Heresbach D, Bernard P, Hochain P, Larricq J, Gourlaouen A, Ribard D, Kara NM, Legoux J-L, Pillegand B, Becker M-C, Di Constanzo J, Metrau J-M, Silvain C, Beauchant M. Sclerotherapy with or without octreotide for acute variceal bleeding. N Engl J Med. 333:1995;555-560.
4. Albillos A, Rossi I, Iborra J, Lledó JL, Challeja JL, Barrios C, Garcia P, Escartin P. Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension. J Hepatol. 21:1994;88-94.
5. Primigani M, Andreoni B, Carpinelli L, Capria A, Rocchi G, Lorenzini I, Staudacher C, Beretta L, Motta R, de Franchis R. Sclerotherapy plus octreotide versus sclerotherapy alone in the prevention of early rebleeding from esophageal varices: a randomized, double-blind, placebo-controlled, multicenter trial. Hepatology. 1:1995;1323-1327.
6. Pedretti G, Elia G, Calzetti C, Magnani G, Fiaccadori F. Octreotide versus terlypressin in acute variceal hemorrhage in liver cirrhosis. Emergency control and prevention of early rebleeding. Clin Invest. 72:1994;653-659.
7. Kravetz D, Bosch J, Terés J, Bruix J, Pimola A, Rodés J. Comparison of intravenous somatostatin and vasopressin infusions in treatment of acute variceal hemorrhage. Hepatology. 4:1984;442-446.
8. McKee R. A study of octreotide in esophageal varices. Digestion. 45:1990;60-65.
9. del Pozo E, Neufeld M, Schlüter K, Tortosa F, Clarenbach P, Bieder E, Wendel L, Nüesch E, Marbach P, Cramer H, Kerp L. Endocrine profile of a long-acting somatostatin derivative SMS 201-995. Studies in normal volunteers following subcutaneous administration. Acta Endocrinol (Copenh). 111:1986;433-439.
10. Lamberts SWJ, Oosterom R, Neufeld M, del Pozo E. The somatostatin analogue octreotide induces long acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab. 60:1985;1161-1165.
11. Kutz K, Nüesch E, Rosenthaler J. Pharmacokinetics of SMS 201-995 in healthy subjects. Scand J Gastroenterol. 21:1986;65-72.
12. Weeke J, Christensen SE, Ørskov H, Kaal A, Pedersen MM, Illum P, Harris AG. A randomized comparison of intranasal and injectable octreotide administration in patients with acromegaly. J Clin Endocrinol Metab. 75:1992;163-169.
13. Osei K, O'Dorisio TM, Malarkey WB, Cataland S. Continous subcutaneous octreotide infusion: dose-response relationships between metabolic effects and octreotide clearance in patients with insulin-dependent (type 1) diabetes. J Lab Clin Med. 118:1991;56-64.
14. Kallivretakis N, Yotis A, del Pozo E, Marbach P, Mountokalakis T, Tolis G. Pharmacokinetics of SMS 201-995 in normal subjects and in patients with severe renal failure. Neuroendocrinol Lett. 7:1985;92.
15. DeLédinghen V, Ripault MP, Silvain C, Beauchant M, Raffoux N, Bouquet S. Subcutaneous octreotide for the prevention of early variceal rebleeding (Letter). Hepatology. 23:1996;938.
16. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 60:1973;646-649.
17. Ørskov H, Thomsen HG, Yde H. Wick-chromatography for rapid and reliable immunoassay of insulin, glucagon and growth hormone. Nature. 219:1968;193-195.
18. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm. 4:1978;395-402.
19. Nicholls J, Wynick D, Domin J, Sandler LM, Bloom SR. Pharmacokinetics of the long-acting somatostatin analogue (SMS 201-995) in acromegaly. Clin Endocrinol. 32:1990;545-550.
20. Winkler K, Bass L, Keiding S, Tygstrup N. The physiological basis for clearance measurements in hepatology. Scand J Gastroenterol. 14:1979;439-448.
21. Ring-Larsen H. Hepatic nephropathy, related to hemodynamics. Liver. 3:1983;265-289.
22. O'Conner MK, Kvols LK, Brown ML, Hung JC, Hayostek RJ, Cho DS, Vetter RJ. Dosimetry and biodistribution of an iodine-123-labeled somatostatin analogue in patients with neuroendocrine tumors. J Nucl Med. 33:1992;1613-1619.
23. Lin H-C, Tsai Y-T, Lee F-Y, Lee S-D, Hsia H-C, Lin W-J, Lo K-J. Hemodynamic evaluation of octreotide in patients with hepatitis B-related cirrhosis. Gastroenterology. 103:1992;229-234.
24. Eriksson LS, Brundin T, Söderlund C, Wahren J. Haemodynamic effects of a long-acting somatostatin analogue in patients with liver cirrhosis. Scand J Gastroenterol. 22:1987;919-925.
25. McCormick PA, Chin J, Greenslade L, Karatapanis S, Dick R, McIntyre N, Burroughs AK. Cardiovascular effects of octreotide in patients with hepatic cirrhosis. Hepatology. 21:1995;1255-1260.
26. Escorsell A, Feu F, Garcia-Pagán JC, Luca A, Bandi JC, Casado M, Bosch J, Rodés J. Hemodynamic effects of octreotide in cirrhotic patients with portal hypertension. A double blind study. J Hepatol. 23:1995;85.
27. Barbare J-C, Poupon R, Jaillon P, Bories P, Aussanaire M, Darnis F, Michel H, Cheynol G. The influence of vasoactive agents on metabolic activity of the liver in cirrhosis: a study of the effects of posterior pituitary extract, vasopressin and somatostatin. Hepatology. 4:1984;59-62.
28. Merkel C, Gatta A, Caregaro L, Sacerdoti D, Rondana M, Ruol A. Effect of somatostatin on liver blood flow and liver metabolic activity in patients with cirrhosis. Scand J Clin Lab Invest. 47:1987;667-672.
29. Lamberts SWJ, van der Lely A-J, de Herder WW, Hofland LJ. Octreotide. N Engl J Med. 334:1996;246-253.
30. Tulassay Z, Tulassay T, Szücs L, Nagy I. Effects of a long acting somatostatin analogue on renal functions. Horm Metab Res. 22:1990;555-556.
31. Pedersen MM, Christensen SE, Christensen JS, Pedersen EB, Mogensen CE, Ørskov H. Acute effects of a somatostatin analogue on kidney function in type 1 diabetic patients. Diabet Med. 7:1990;304-309.
32. ® (SMS 201-995) in healthy volunteers. Acta Endocrinol (Copenh). 120:1989;708-714.
33. Mountokalakis T, Kallivretakis N, Mayopoulou-Sumvoulidou D, Karvountzis G, Tolis G. Enhancement of renal function by a long-acting somatostatin analogue in patients with decompensated cirrhosis. Nephrol Dial Transplant. 3:1988;604-607.
34. Rodriguez-Perez F, Albillos A, Groszmann RJ. Octreotide improves renal function, total exchangeable sodium and peripheral hemodynamics in cirrhotic patients with ascites [Abstract]. Gastroenterol. 104:1993;980.
35. Selzer R, Dudley F. Effects of octreotide on renal function in cirrhosis: reversal with glucagon [Abstract]. Hepatology. 18:1993;102.
36. Ginès A, Salmerón JM, Ginès P, Jiménes W, Saló J, Piera C, Clària J, Rivera F, Arroyo V, Ródes J. Effects of somatostatin on renal function in cirrhotics. Gastroenterology. 103:1992;1868-1874.
37. Hülagü S, Demirtürk L, Yazgan Y, Altin M, Gürbüz AK, Gültepe M, Ozel M, Sayan O, Danaci M, Tülbek Y. Effect of Octreotide on renal function in patients with decompensated liver cirrhosis [Abstract]. Endoscopy. 27:1995;S8.
38. 51Cr]EDTA plasma clearance determination in patients with ascites. Scand J Clin Lab Invest. 40:1980;279-284.
39. ® in the Treatment of Acromegaly. 1987;83-87 Springer-Verlag, Amsterdam.
40. Gibaldi M, Perrier D. Multicompartment Models. Gibaldi M, Perrier D. Pharmacokinetics. Drugs and the Pharmaceutical Sciences. 15:1982;45-111 Marcel Dekker, New York.
41. Freedman LS, Workman P. When can the infusion period be safely ignored in the estimation of pharmacokinetic parameters of drugs in humans? Cancer Chemother Pharmacol. 22:1988;95-103.